Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzheimer’s disease-fighting antibody, which the ...

Ionis Pharmaceuticals (IONS) stock slips as Novartis (NVS) delays Phase 3 trial data for its cardiac therapy pelacarsen. Read ...

Deals, pipeline updates and geopolitical issues drove the conversation at the 2025 JP Morgan Healthcare conference.

The president offered a proclamation Saturday to begin duties on Canada, Mexico, and China. Musk says Tesla's robotaxis will hit Austin this summer. But after years of unfulfilled promises, investors ...

Amgen's dividend yield remains attractive, with a moderate payout ratio and strong free cash flow. Click here to see why AMGN ...

Novartis AG (NYSE:NVS), a global healthcare powerhouse with a market capitalization of $208.27 billion, has recently transformed into a pure-play pharmaceutical company, sharpening its focus on its ...

GSB, organised a five-day e-Faculty Development Program (e-FDP) on the topic ‘Emerging Technologies: Augmenting Pharmaceutical Horizon’ where 179 registrants from 56 colleges across six states came ...

In addition, EGEIRO Pharma has approached investors to extend the company’s cash flow horizon and has received an expression of interest for a potential investment of 2 million euros. EGEIRO Pharma ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Each time there is a correction, especially one that lasts a few months like the current one, investors get divided into two ...

Novo Nordisk and Eli Lilly have used submissions to the federal government’s budget process to argue reducing obesity will be ...